Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 CountriesReportar como inadecuado




Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.

Methods

This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD treated and those requiring emergency department visits and-or hospitalisation, contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.

Results

The annual direct costs of COPD ranged from $504 South Korea to $9,981 USA, with inpatient hospitalisations 5 countries and home oxygen therapy 3 countries being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% Italy to 52% USA and UK with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 Russia to $30,826 USA but a consistent pattern across countries showed greater costs among those with increased burden of COPD symptoms, health status and more severe disease and a greater number of comorbidities.

Conclusions

The economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.



Autor: Jason Foo, Sarah H. Landis, Joe Maskell, Yeon-Mok Oh, Thys van der Molen, MeiLan K. Han, David M. Mannino, Masakazu Ichinose, Yog

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados